In NSCLC, TAMs could promote tumor cell glycolysis by TNFα secretion and facilitate tumor hypoxia by increasing AMPK and PGC-1α, leading to decreased PD-L1 of tumor cells and T-cell infiltration in TME to cause immunotherapy resistance (87). This evidence concerns the gene TNF and neoplasm.